Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanara MedTech (SMTI) Cash & Equivalents (2016 - 2025)

Sanara MedTech's Cash & Equivalents history spans 15 years, with the latest figure at $16.6 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 4.41% year-over-year to $16.6 million; the TTM value through Dec 2025 reached $16.6 million, up 4.41%, while the annual FY2025 figure was $16.6 million, 4.41% up from the prior year.
  • Cash & Equivalents reached $16.6 million in Q4 2025 per SMTI's latest filing, up from $14.9 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $27.3 million in Q1 2021 to a low of $2.8 million in Q1 2024.
  • Average Cash & Equivalents over 5 years is $13.8 million, with a median of $15.4 million recorded in 2024.
  • Peak YoY movement for Cash & Equivalents: soared 3996.23% in 2021, then tumbled 61.18% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $18.7 million in 2021, then plummeted by 51.97% to $9.0 million in 2022, then plummeted by 42.55% to $5.1 million in 2023, then skyrocketed by 208.48% to $15.9 million in 2024, then rose by 4.41% to $16.6 million in 2025.
  • Per Business Quant, the three most recent readings for SMTI's Cash & Equivalents are $16.6 million (Q4 2025), $14.9 million (Q3 2025), and $17.0 million (Q2 2025).